Pergamon

*Tetrahedron: Asymmetry* Vol. 6, No. 12, pp. 2893-2894, 1995

0957-4166/95 $9.50+0.00

0957-4166(95)00378-9

# SYNTHESIS AND ABSOLUTE CONFIGURATION OF (+)-2,3,3-TRIMETHYL-2-HYDROXYBUTANOIC ACID

Saleem Ahmad,* Steven H. Spergel, Joel C. Barrish, John DiMarco and Jack Gougoutas
Bristol-Myers Squibb Pharmaceutical Research Institute
P.O. Box 4000, Princeton, NJ 08543

**Abstract:** The absolute configuration of (+)-2,3,3-trimethyl-2-hydroxybutanoic acid, a key intermediate in the synthesis of the HIV-protease inhibitor **1a** (isomer A), has been confirmed as (*R*) on the basis of X-ray analysis.

During the course of our efforts to prepare potent inhibitors of the HIV-protease, we observed a 22-fold difference in the intrinsic activities of the two diastereomeric α-hydroxyamides **1a** and **1b**.[1] In order to determine the absolute stereochemistry of the more potent isomer **1a**, and to develop a stereoselective synthesis of this compound, we sought to prepare each enantiomer of the intermediate α-hydroxy acid **2**. A search of the chemical literature revealed an enantioselective synthesis of the dextrorotatory enantiomer **(+)-2** *via* a chiral oxathiane auxiliary reported by Eliel and Lynch.[2] The authors assigned the (*R*)-configuration to this compound based on Cram's, Prelog's and Sharpless' rules. However, the dextrorotatory compound had previously been characterized as the (*S*)-enantiomer.[3] While there was strong evidence that this earlier work was in error, some degree of ambiguity remained regarding the optical rotation associated with a particular absolute configuration. In fact, Eliel and Lynch reported that they could not prepare a crystalline intermediate to unequivocally provide the absolute configuration of **(+)-2**. Herein we report an asymmetric synthesis of **(+)-2** *via* Sharpless epoxidation along with a proof for assignment of the (*R*)-configuration from X-ray crystallography.



**1a** (isomer A) $IC_{50}$ = 40 nM
**1b** (isomer B) $IC_{50}$ = 900 nM



**2**

The synthesis of **(+)-2** is outlined in Scheme 1. Allylic oxidation of 2,3,3-trimethyl-1-butene (**3**) using $SeO_2$ and *t*-BuOOH in the presence of salicylic acid[4] afforded the corresponding allylic alcohol (33% yield) which was converted to the chiral epoxide **4** (73% yield) *via* Sharpless epoxidation with diethyl D-(-)-tartrate.[5] The epoxide **4** was treated with LAH in ether to give the diol **5** in 81% yield.[6] Swern oxidation of **5** afforded the corresponding α-hydroxy aldehyde in quantitative yield which was converted *via* Lindgren oxidation[7] to the hydroxy acid **(+)-2** ($[\alpha]_D$ = +3.8 , C = 5, $CH_2Cl_2$)[8] in 65% yield after recrystallization from hexane.

Treatment of the L-phenylalanine-derived epoxide **6**[1] with sodium azide gave the azido alcohol **7**, which was converted in two steps to the α-hydroxyamide **8** *via* acid catalyzed removal of the Boc group followed by amide coupling of the resulting amine with **(+)-2**. A single crystal X-ray analysis (Figure 1) of **8** unambiguously confirmed that the dextrorotatory enantiomer **(+)-2** has the (*R*)-configuration as predicted by Eliel and Lynch.

**Scheme I.**




a) $SeO_2$/t-BuOOH/salicylic acid, 33%; b) diethyl D-(-)-tartrate/Ti(i-PrO)$_4$/4Å molecular sieves/t-BuOOH, 73%; c) LAH/ether, 81%; d) oxalyl chloride/DMSO/$Et_3N$/$CH_2Cl_2$; e) $NaClO_2$/$NH_2SO_3H$/THF-$H_2O$, 65%; f) $NaN_3$/MeOH/$NH_4Cl$, 92%; g) HCl/EtOAc, 100%; h) ***(R)*-(+)-2**/BOP reagent/NMM/DMF, 45%



**Figure I.** The Solid State Conformation of **8** as Determined by X-Ray Analysis.

**References and Notes:**


1) a) Barrish, J. C..; Gordon, E.; Alam, M.; Lin, P.-F.; Bisacchi, G. S.; Chen, P.; Cheng, P. T. W.; Fritz, A. W.; Greytok, J. A.; Hermsmeier, M. A.; Humphreys, W. G.; Lis, K. A.; Marella, M. A.; Merchant, Z.; Mitt, T.; Morrison, R. A.; Obermeier, M. T.; Pluscec, J.; Skoog, M.; Slusarchyk, W. A.; Spergel, S. H.; Stevenson, J. M.; Sun, C.-Q.; Sundeen, J. E.; Taunk, P.; Tino, J. A.; Warrack, B. M.; Colonno, R.; Zahler, R. *J. Med. Chem.* **1994**, *37*, 1758. b) Bisacchi, G. S.; Ahmad, S.; Alam, M.; Ashfaq, A.; Barrish, J.; Cheng, P. T. W.; Greytok, J.; Hermsmeier, M.; Lin, P.-F.; Merchant, Z.; Skoog, M.; Spergel, S.; Zahler, R. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 459. c) Ahmad, S.; Ashfaq, A.; Alam, M.; Bisacchi, G. S.; Chen, P.; Cheng, P. T. W.; Colonno, R.; Greytok, J.; Hermsmeier, M.; Lin, P. F.; Lis, K. A.; Merchant, Z.; Mitt, T.; Skoog, M.; Spergel, S.; Tino, J. A.; Vite, G. D.; Zahler, R.; Barrish, J. C. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 1729.
2) Eliel, E. L.; Lynch, J. E. *Tetrahedron Lett.* **1987**, *28*, 4813; and references cited therein.
3) Evans, R. J. D.; Landor, S. R. *J. Chem. Soc.* **1965**, 2553. b) Evans, R. J. D.; Landor, S. R.; Smith, R. T. *J. Chem. Soc.* **1963**, 1506.
4) Umbreit, M. A.; Sharpless, K. B. *J. Am. Chem. Soc.* **1977**, *99*, 5526.
5) Gao, Y.; Hanson, R. M.; Klunder, J. M.; Ko, S. Y.; Masamune, H.; Sharpless, K. B. *J. Am. Chem. Soc.* **1987**, *109*, 5765.
6) Eliel and Lynch (see ref. 2, footnote 13) reported that compound **5** has been synthesized *via* a similar approach by Prof. W. Baldwin.
7) Lindgren, B. O.; Nilsson, T. *Acta. Chem. Scand.* **1973**, *27*, 888.
8) The enantiomeric excess of this material was found to be 96% as determined by chiral HPLC analysis of the corresponding 4-nitrophenyl ester (Daicel CHIRALCEL OD column/hexane-ether-ethanol 80:19:1).


(*Received in USA* 19 *July* 1995; *accepted* 9 *October* 1995)